-
公开(公告)号：NO20025107L
公开(公告)日：2002-12-19
申请号：NO20025107
申请日：2002-10-24
Applicant: ABBOTT LAB
Inventor： SCHRIMPF MICHAEL R , TIETJE KARIN R , TOUPENCE RICHARD B , JI JIANGUO , BASHA ANWER , BUNNELLE WILLIAM H , DAANEN JEROME F , PACE JENNIFER M , SIPPY KEVIN B
IPC: C07D231/54 , A61K31/454 , A61K31/4545 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/34 , C07D471/04 , C07D487/04 , C07D487/00
Abstract: Compounds of formula (I), pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals
-
公开(公告)号：BR0107246A
公开(公告)日：2002-10-01
申请号：BR0107246
申请日：2001-04-27
Applicant: ABBOTT LAB
Inventor： SCHRIMPF MICHAEL R , TIETJE KARIN R , TOUPENCE RICHARD B , JI JIANGUO , BASHA ANWER , BUNNELLE WILLIAM H , DAANEN JEROME F , PACE JENNIFER M , SIPPY KEVIN B
IPC: C07D231/54 , A61K31/454 , A61K31/4545 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/34 , C07D471/04 , C07D487/04 , C07D487/00
Abstract: Compounds of formula (I), pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals
-
公开(公告)号：SK5542001A3
公开(公告)日：2001-12-03
申请号：SK5542001
申请日：1999-10-27
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J , COGHLAN MICHAEL J , STEWART ANDREW O
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号：UY26683A1
公开(公告)日：2001-11-30
申请号：UY26683
申请日：2001-04-25
Applicant: ABBOTT LAB
Inventor： SCHRIMPF MICHAEL R , JI JIANGUO , DAANEN JEROME F , TIETJE KARIN R , BASHA ANWER , PACE JENNIFER MARY , TOUPENCE RICHARD B , BUNNELLE WILLIAM H , SIPPY KEVIN B
Abstract: Compuestos de fórmula I: composiciones farmacéuticas de estos compuestos, y el uso de dichas composiciones para controlar la transmisión sináptica en mamíferos.
-
公开(公告)号：NO20012061D0
公开(公告)日：2001-04-26
申请号：NO20012061
申请日：2001-04-26
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J , COGHLAN MICHAEL J , STEWART ANDREW O
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06 , C07D
Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
Patent Agency Ranking116.发明专利
公开(公告)号：CZ2000446A3
公开(公告)日：2000-05-17
申请号：CZ2000446
申请日：1998-08-10
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , RHODE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
117.发明专利
公开(公告)号：CZ20000446A3
公开(公告)日：2000-05-17
申请号：CZ20000446
申请日：1998-08-10
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , RHODE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
CPC classification number: C07D401/06 , C07D237/14 , C07D237/18 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D409/06 , C07D409/12 , C07D417/06
-
公开(公告)号：AU6523099A
公开(公告)日：2000-05-15
申请号：AU6523099
申请日：1999-10-27
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J , COGHLAN MICHAEL J , STEWART ANDREW O
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
-
公开(公告)号：CA2347982A1
公开(公告)日：2000-05-04
申请号：CA2347982
申请日：1999-10-27
Applicant: ABBOTT LAB
Inventor： LIU HUAQING , KOLASA TEODOZYJ , BASHA ANWER , KORT MICHAEL E , STEWART ANDREW O , PATEL MEENA V , ROHDE JEFFREY J , MCCARTY CATHERINE M , COGHLAN MICHAEL J , BLACK LAWRENCE A
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号：NO20000863L
公开(公告)日：2000-02-22
申请号：NO20000863
申请日：2000-02-22
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
-
-
-
-
-
-
-
-
Search Results
131
records
(took 0.023 seconds)
